Handelsavisen
prelaunch
Companies ›Healthcare ›4105.TWO
41
4105.TWO — TPEx Pharmaceuticals

TTY Biopharm Co Ltd

$73,50
Open in Charts → Attach watcher ⌖
— —
TWD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
18,3B TWD
P/E
—
EV / Rev
—
Div yield
6,06 %
Op margin
26,1 %
ROE
21,5 %
Net margin
24,2 %
Debt / equity
0,17
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

TTY Biopharm Co Ltd is a pharmaceutical company that develops and commercializes biopharmaceutical products, primarily generating revenue through the sale of prescription drugs and related healthcare solutions.

Business. TTY Biopharm Co Ltd (4105.TWO) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm is headquartered in Taiwan and is primarily listed on the Taiwan Premium Exchange (TPEx). Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY2 analysts
1 buy1 hold0 sell
Avg 12m price target90,00

Analyst recommendations

2 analysts · consensus Buy
Buy1
Hold1
Sell0
12-month price target
90,00
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
2 analysts · indicative
Ownership
—
not yet wired
Profitability→
21,5 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 4105.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 4105.TWO. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    TTY Biopharm Co Ltd (4105.TWO) is a pharmaceutical company engaged in the research, development, and sale of pharmaceutical products. The firm is headquartered in Taiwan and is primarily listed on the Taiwan Premium Exchange (TPEx). Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    TTY Biopharm maintains a strong liquidity position, with a current ratio of 2.28 and cash and equivalents of TWD 1.26 billion, which supports its operational flexibility. The company's price-to-book ratio of 2.54 and price-to-tangible-book ratio of 2.54 indicate that the market values the company at a premium to its book value, suggesting confidence in its intangible assets and future earnings potential. The debt-to-equity ratio of 0.17 reflects a conservative capital structure, with long-term debt at TWD 1.22 billion and total equity at TWD 7.24 billion.

    In terms of profitability, TTY Biopharm's return on equity of 21.54% and return on assets of 13.74% outperform the typical benchmarks for the pharmaceutical industry, indicating efficient use of equity and assets to generate returns. The company's gross profit of TWD 3.72 billion and operating income of TWD 1.69 billion support its strong margins, which are key drivers of its profitability.

    The company's revenue is concentrated in its core pharmaceutical business, with no disclosed geographic diversification in the latest financial data. This concentration may expose the company to regional market risks, particularly in its primary operating region. However, the absence of disclosed geographic breakdowns limits the ability to assess the extent of regional exposure.

    Looking ahead, TTY Biopharm is projected to experience growth in the current fiscal year, with revenue expected to increase by a double-digit percentage. The company's free cash flow of TWD 646 million and operating cash flow of TWD 1.76 billion provide a solid foundation for reinvestment and shareholder returns. Analysts have set a mean price target of TWD 90.00, indicating a potential upside from the current market price of TWD 73.90.

    The company's risk profile is characterized by low liquidity and dilution risks, with no immediate filing-based flags detected. The conservative capital structure and strong cash reserves mitigate liquidity concerns. Additionally, the absence of dilution risks suggests that the company is not currently planning significant equity issuances that could dilute existing shareholders.

    Recent filings and transcripts have not revealed any material events that would significantly impact the company's operations or financial performance. The company's financial health and strategic direction appear stable, with no major disruptions reported in the latest disclosures.

    Key takeaways
    • TTY Biopharm has a strong liquidity position with a current ratio of 2.28 and TWD 1.26 billion in cash and equivalents.
    • The company's return on equity of 21.54% and return on assets of 13.74% indicate efficient use of capital.
    • The conservative debt-to-equity ratio of 0.17 suggests a stable capital structure with minimal leverage.
    • Analysts project a mean price target of TWD 90.00, indicating a potential upside from the current market price.
    • The company's risk profile is low, with no immediate liquidity or dilution concerns.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $73,50
    Market cap
    $18.38B
    Enterprise valueⓘ
    $18.33B
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    10.4x
    P / Bⓘ
    2.5x
    P / Tangible bookⓘ
    2.5x
    Tangible book
    $7.24B
    Net cashⓘ
    $41.5M
    Current ratioⓘ
    2.3
    Debt / equityⓘ
    0.2
    ROAⓘ
    13.7%
    ROEⓘ
    21.5%
    Cash conversionⓘ
    113.0%
    CapEx / revenueⓘ
    -2.3%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    7,03
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    2
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    as of 2026-05-24 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPS—no estimate—no estimate7,03
    Revenue—no estimate—no estimate7,1B TWD
    Operating income—no estimate—no estimate2,1B TWD
    Full-year consensus mean (period as reported by source) · consensus in TWD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution2 analysts
    Strong buy0
    Buy1
    Hold1
    Sell0
    Strong sell0
    12-month price target$90,00 · Median $90,00
    Low $88,00High $92,00
    Operating income · consensus2,1B TWD
    EPS surprise
    −10,9 %
    reported vs consensus · miss
    Revenue surprise
    −8,7 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$88,00
    Mean$90,00
    Median$90,00
    High$92,00
    Spot$73,50
    +22.4 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin26,1 %Above P75
    Net Margin24,2 %Above P75
    ROE21,5 %Best in class
    Capex / Rev-2,3 %Above median
    D/E0,17Below median
    Cash Conv1,13Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Ev To Operating Cash Flow
      enterprise_value / operating_cash_flow
    • Return On Equity
      net_income / total_equity
    • Price To Earnings
      market_price / (net_income / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    Source documents
    • TTY Biopharm Co Ltd Market data — financials · 2026-05-26
    • TTY Biopharm Co Ltd Market data — analyst estimates · 2026-05-26
    • TTY Biopharm Co Ltd Market data — ESG · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    4105.TWOCanonical
    TPEx · TWD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage